![](https://www.fedaiisf.it/wp-content/uploads/2015/04/fedaiisf-ARCHIVIO-STORICO-780x450.jpg)
by Domenico De Felice | July 3, 2013 | Society
There Supreme Court of the United States of America rejected a compensation to the small town Karen Barlett of New Hampshire for a serious event, as admitted by the Court itself, caused by taking a painkiller generic. The same Supreme Court, in 2009, had instead established that patients who believed they were damaged could bring the manufacturers of brand name drugs. As if to say that since i generic drugs are marketed on the basis of the corresponding brand-name drugs, which need to be tested, only brand-name drugs can be subject to trial. In short, it doesn't matter what makes up the generic drug, the blame remains with the branded drug from which it derives! In Use the80% on the market is generics and if patients have serious complications it doesn't matter. In Italy the market share of the generic is around 20%. All over the world it is necessary to save on the cost of medicines without risking, in my opinion, the health of citizens.
But wouldn't it be easier to know exactly the composition of generics as an active ingredient and excipients? Couldn't they be exactly the same and cost less due to poor packaging, if not absent, lack of marketing studies or something else? It couldn't be save on the expenses of very expensive medical congresses in pleasant places that have nothing to do with the health of the citizens? Who plays on the health of patients?
It would be enough for the pharmaceutical industries to produce a single drug,specificfor each pathology to a balanced social cost for essential and chronic pathologies. The others were at a higher cost to reduce abuse and "buffer stock”